{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:02:33Z","timestamp":1780333353725,"version":"3.54.1"},"reference-count":32,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"abstract":"<jats:p>Introduction: Omalizumab is an effective add-on therapy for chronic spontaneous urticaria (CSU) refractory to antihistamines. However, biomarkers predicting treatment response remain unclear. This 10-year real-life, retrospective study aimed to assess the efficacy and safety of omalizumab in CSU and to identify predictors of treatment response, particularly focusing on total IgE levels. Methods: We included 221 adult CSU patients treated with omalizumab between 2015 and 2024. Clinical response was evaluated using Urticaria Activity Score over 7 days (UAS7) and Urticaria Control Test (UCT). Treatment response was categorized as rapid, late, or non-response. Laboratory parameters, including total IgE, eosinophils, and thyroid autoantibodies, were analysed in relation to treatment outcomes. Results: Omalizumab provided rapid or late responses in 98.2% of patients, with significant reductions in UAS7 and improvements in UCT scores over time. Only 1.8% were non-responders. A total IgE level \u226412.5 IU\/mL was identified as a strong predictor of non-response (AUC: 0.903), with 75.0% sensitivity and 96.7% specificity. Multivariate logistic regression revealed that lower total IgE levels independently predicted non-response (OR: 0.032, p = 0.031). Conclusion: Omalizumab is effective and safe in real-life CSU management, even among patients with comorbidities such as autoimmune diseases and malignancies. Low total IgE levels may serve as a reliable biomarker for predicting non-response and guiding individualized treatment strategies.<\/jats:p>","DOI":"10.1159\/000548107","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:01:22Z","timestamp":1756396882000},"page":"605-615","source":"Crossref","is-referenced-by-count":1,"title":["Low Total IgE Predicts Non-Response to Omalizumab in Chronic Spontaneous Urticaria: A 10-Year Real-Life Study"],"prefix":"10.1159","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6858-6824","authenticated-orcid":false,"given":"Zeynep","family":"Yegin Katran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smet","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda\u00e7","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.11.016"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.15568"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae264"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13368"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20941"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2024.1451296"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.147"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.23822\/eurannaci.1764-1489.379"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2329784"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100719"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000535414"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.283"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0323"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2024.4600"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/all.16334"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18574"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.3447"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00641-6"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100721"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.10.030"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02170-4"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.11.005"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12632"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2024.02.006"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad386"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16593"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.230092"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100386"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01040-9"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.5021\/ad.24.004"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.06.014"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000548107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:04:42Z","timestamp":1780329882000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000548107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000548107","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}